New Delhi: Recommending to conduct post marketing surveillance (PMS) study in India, the Subject Expert Committee (SEC) ...

One in five older Indian adults had diabetes in 2019, says a Lancet study. What are the key highlights of the study? What is ...

In the 72-week phase 3 ATTAIN-1 trial, the once-daily oral GLP-1 receptor agonist orforglipron led to substantial weight loss ...

Significant regulatory advances for lead candidate EB613 streamline Phase 3 clinical development and reduce regulatory hurdles. These 10 stocks could mint the next wave of millionaires › Entera Bio ...

In Oklahoma, approximately 405,800 adults have diabetes, and every year, about 26,000 adults in the state are diagnosed with the disease, according to the American Diabetes Association. In America, ...

Weight-loss drugs spur debate and open new doors for CU Anschutz researcher studying food/brain relationshipOccasionally ...

Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight ...

With salty snack dollars slumping, leveraging ‘sweet spots’ and navigating the ‘snackscape’ could help regain share ...

Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 ...

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...

GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

Weight loss of at least 5% was associated with improvements in PROs among individuals with RMDs taking weight loss medications.